Increased Energy Requirements during onset of Guillain-Barré Syndrome – A Case Study by Jamieson, Rebekah
I. Literature Review 
Overview of Guillain-Barré Syndrome 
Guillain-Barré syndrome (GBS) is an inflammatory disorder that affects the peripheral nervous 
system1. An immune-mediated attack of peripheral nerve cells occurs during GBS onset 
characterized by infiltration of white blood cells. The immune attack results in inflammation of 
nervous tissue, demyelination of nerve cells, and axonal degeneration2.  
The peripheral nervous system (PNS) is composed of nerves located outside the brain and spinal 
cord and functions to connect the central nervous system to the limbs and organs. Neurons of the 
PNS are surrounded and protected by glial cells, which are non-neuronal cells that maintain 
homeostasis and form myelin. The principal glial cells of the PNS are Schwann cells. 
Myelinating Schwann cells wrap around axons of motor and sensory neurons to form the myelin 
sheath. Myelin is a specialized fatty insulation that envelops axons, the part of nerve cells 
involved in signal conduction3 (Figure 1). In GBS, the immune system mounts an attack against 
myelin. When the neuron is demyelinated its ability to conduct signals is severely impaired, 
resulting in a neuropathy characterized by muscular weakness and distal sensory loss4. In GBS 
and other medical conditions where PNS nueron myelin sheaths are injured or degraded, nerves 
cannot transmit signals efficiently, and muscles begin to lose their ability to respond to 
commands relayed from the central nervous system.  
 
Figure 1 Structure of a Schwann Cell. Adapted from Campbell Biology. Copyright 2014 Pearson 
Education, Inc. 
One or two cases of GBS per 100,000 people are reported each year2. GBS affects males more 
frequently than females, and its incidence increases with advancing age. GBS has been 
characterized as a syndrome rather than a disease due to lack of a specific disease-causing agent1. 
The symptoms can be varied, making it difficult to diagnose GBS in its early stages. GBS is 
often diagnosed by a clinical pattern of sudden onset weakness on both sides of the body and 
elevated protein in the cerebrospinal fluid without increase of white blood cells5. Protein 
elevation is thought to be due to inflammation of nerve cells leaving the central nervous system. 
Autonomic nervous system involvement occurs in many cases and can cause urine retention, 
ileus, tachycardia, hypertension, arrhythmia, and orthostatic hypotension6. 
A number of subtypes of GBS are recognized including acute inflammatory demyelinating 
polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor and sensory 
axonal neuropathy (AMSAN). However, many patients experience symptoms that overlap 
subtypes, and classification is often difficult. In addition, all subtypes can occur in partial forms5. 
The most common subtype in Europe and North America is acute inflammatory demyelinating 
polyneuropathy. In the AIDP subtype, the immune system reacts to antigenic determinants 
present on Schwann cells or myelin that lead to immune attack and result in demyelination2. The 
etiology is not completely understood, but it is believed to have an autoimmune origin which is 
triggered by an infection that stimulates anti-ganglioside antibody production in most cases1. 
Numerous case reports have identified possible infections and other events as antecedents of 
GBS. Case control studies have consistently confirmed Campylobacter jejuni and 
cytomegalovirus as the most common precipitants of GBS6. When GBS is preceded by an 
infection, it is thought that the virus changes the nature of neurons so the immune system treats 
them as foreign. Another thought is that the virus alters the immune system so it is less 
discriminating towards its own cells, allowing immune cells to infiltrate5. 
GBS reveals itself in a matter of days. The common clinical pattern is an ascending paralysis 
first noticed as loss of tendon reflexes in the lower extremities, which evolves over hours to days 
with numbness in all extremities. Lower limbs are affected more than upper limbs, and facial 
paralysis occurs in 50% of individuals1. The clinical course is similar regardless of subtype, 
although AIDP GBS after Campylobacter infection tends to lead to more severe symptoms than 
other identified antecendents4. The maximum severity of symptoms is usually seen in 2-4 weeks, 
often referred to as the acute stage1. Vital capacity and swallowing may also rapidly deteriorate 
to a point where intensive care becomes necessary4.  
AIDP in particular has been identified as an inflammatory process involving a large portion of 
the PNS. Activated white blood cells migrate across a delicate layer of connective tissue 
surrounding the myelin sheath and attract macrophages. Macrophages then penetrate Schwann 
cells and digest the myelin, leaving demyelinated axons. The location of neuron degradration 
accounts for the distribution of associated symptoms6. Demyelinating forms of GBS are 
characterized not only by macrophage-induced demyelination, but also by T-cell and plasma cell 
infiltration into peripheral neurons7.  
Activation of T-cells is evident in GBS by the increased number of circulating cells that bear 
activation markers, as well as increased concentrations of the interleukin-2-receptor expressed on 
the surface of immune cells. Inflammation seen in AIDP may be a consequence of the 
inflammatory mediators secreted by activated macrophages or T cells. One of the most powerful 
cytokines, TNFα, has often been proposed to have a direct role in mediating demyelination. 
TNFα has been found in high concentrations in serum during the acute stage of GBS6. The 
release of TNFα during the acute phase of GBS is also consistent with a systemic stress 
response8.  
No cure exists for GBS, but available therapies can lessen symptoms and accelerate recovery. 
The most common therapies are plasma exchange (commonly called plasmapheresis or PLEX 
therapy) and high-dose immunoglobulin therapy. Both are effective, but immunoglobin therapy 
is easier to administer. In high-dose immunoglobulin therapy, a patient receives intravenous 
injections of immunoglobulin proteins. High doses lessen immune attack on the nervous system 
by saturating receptors on macrophages, suppressing antibodies, and suppressing inflammatory 
mediators. The alternative therapy is plasmapheresis, a method by which blood is removed from 
the body and processed. Red and white blood cells are separated from the plasma, and blood 
cells are returned to the patient while the plasma is not. Plasmapheresis is thought to be effective 
because antibodies and other immune cell-derived factors that contribute to nerve damage in 
GBS are removed5. 
Nutritional Needs in Guillain-Barré syndrome  
During the first 1-2 weeks of acute onset, the metabolic response in GBS is similar to the stress 
response seen after a neurotrauma. When energy needs are determined by indirect calorimetry, 
the range may be as high as 40-45 kcal/kg compared with the typical requirement of 25-30 
kcal/kg. In addition, protein needs could be as much as twice the normal amount because of 
accelerated protein breakdown4. The inability to protect body protein stores is seen in other 
inflammatory diseases as well. Impaired utilization of ketones for energy production during GBS 
is thought to be mediated by cytokines such as TNFα and interleukin-1beta9.  
The impression that GBS patients are well nourished frequently delays the initiation of nutrition 
support. Typically, however, GBS patients have already experienced protein depletion at the 
time of admission. Depletion has been found to depend on the severity of the syndrome9. In 
addition, the muscles of the throat are affected in a small percentage of patients, leading to 
dysphagia. Difficulty swallowing further indicates the necessity of nutritional intervention for 
patients with GBS 4.  
Providing adequate nutrition during GBS is important, specifically to abate losses of respiratory 
skeletal muscle. The main cause of death in GBS is adult respiratory distress syndrome, which 
can necessitate ventilator support. When nutrition support is inadequate, patients are more 
susceptible to respiratory compromise due to decreased immunocompetence, muscle atrophy, 
and reduced respiratory muscle endurance. Inadequate nutrition support also increases the risk 
for pressure ulcers, fluid and electrolyte abnormalities, and infections9. 
Hypermetabolism and hypercatabolism decline over the course of the disease, and recovery is 
expected for most patients9. Although full motor recovery is expected in ~60% of patients, more 
than 15% of patients have residual moderate-to-severe weakness 1 year after disease onset, and 
10% die despite intervention and treatment. Many patients experience sensory deficits and do not 
return to their previous functional level. When a patient fully recovers, recurrence of GBS is less 
than 5%7.  
II. Description of the patient 
The patient was a 57-year-old Caucasian male. He was single and lived in a home he owned. 
Before his illness, he worked as a security guard at a correctional facility for 20 years. Prior to 
this, he was a professional wrestler. In general, the patient was physically active, and he often 
commented on how difficult the onset of GBS was due to his previous lifestyle. The patient 
drank 6-12 beers each night at home but did not experience overt withdrawal symptoms during 
the course of his hospital admission. The patient had a medical history of anxiety, 
tachyarrhythmia, and arthritis but was not taking any routine medications prior to admission. 
III. Course of the patient 
A week prior to hospital admission, the patient experienced urinary retention. An outpatient 
physician placed a temporary catheter, and the patient was given Flomax to relax bladder 
muscles and ease urination. After a few days, the patient noticed right arm numbness, which 
progressively spread to the rest of his body. A week after his outpatient visit, he was unable to 
walk due to weakness, so he called EMS personnel who took him to the emergency room. His 
spinal fluid protein was mildly elevated, giving him a clinical picture consistent with GBS, so he 
was transferred to Mission Memorial Hospital Medical/Surgical Intensive Care Unit (MSICU). 
No GBS subtype or antecedent infection was identified for the patient.  
The day after admission the patient began intravenous immunoglobin (IVIG) therapy, the typical 
intervention for patients who present with GBS. IVIG was administered daily for 5 consecutive 
days. When admitted to the MSICU, the patient felt numb throughout his body and was unable to 
move his legs. Speech therapy was consulted on day 2 of admission to assess if he was able to 
swallow due to muscle weakness and numbness. A bedside swallow evaluation indicated that he 
had normal swallow function, and he was cleared for a regular oral diet and a full range of 
liquids for meals.  
Five days after admission, the patient felt weaker and complained of difficulty swallowing. A 
videoflouroscopic swallow study (VFSS) was ordered to assess swallowing capacity. The VFSS 
did not show any differences from the prior bedside swallow study, so a regular diet and full 
range of liquids was still provided. On day 5, the patient also had an extremely low serum 
sodium level of 119 mEq/L (normal range 135-145 mEq/L), which was suspected to be due to 
the syndrome of inappropriate antidiuretic hormone secretion (SIADH), a side effect commonly 
seen during GBS onset. Intravenous hypertonic saline was administered to raise sodium levels.  
After 5 days of IVIG therapy, little to no changes were observed in the patient’s functional 
capacity, so the treatment was extended to 7 days. On day 5, the patient was transferred out of 
the MSICU to a step down unit within the hospital because he was medically stable and did not 
require critical care.  
Eight days after admission, the patient experienced acute hypoxemic respiratory failure and 
returned to the MSICU for observation. Respiratory distress occurred when the patient felt a 
buildup of mucus in his esophagus that he was unable to clear after consuming liquid through a 
straw. In the MSICU, speech therapy was consulted again due to respiratory difficulty arising 
after swallowing. At this stage no differences were observed in swallowing capacity, but the 
speech therapist warned that the patient was at risk for swallow difficulty due to progressive 
weakness that could eventually affect throat muscles. On day 9 of hospitalization, the patient was 
no long able to lift his arms, but he continued to have functionality of his head and neck. 
Day 11 of admission, hypertonic saline was discontinued because his sodium level returned to 
the normal range. Before the patient returned to the step down unit on day 11, the speech 
therapist repeated a VFSS, which showed mild pharyngeal dysphagia, and the texture of his diet 
was modified to chopped meats. Speech therapy saw the patient on day 15 and noted that the 
patient was tolerating the recommended modified diet but required full assistance while eating 
due to full paralysis of his arms.  
2 weeks after admission, after 7 days of IVIG therapy and no marked improvement to the 
patient’s functional capacity, plasmapheresis (PLEX) therapy began. PLEX took place every 
other day for a total of 5 treatments. The patient again experienced respiratory difficulty on the 
day of PLEX initiation and complained of shortness of breath and trouble swallowing. He 
aspirated on water, was no longer deemed safe for an oral diet, and was intubated and transferred 
to the MSICU. Upon his return to the ICU, enteral nutrition was initiated. The patient remained 
in the MSICU for the remainder of his hospitalization due to need of respiratory support. 
Day 19 after admission, a tracheotomy tube was placed to assist with his ongoing difficulty 
breathing so the endotracheal tube placed on day 14 could be removed. In addition, a 
percutaneous endoscopic gastrostomy tube (PEG) was placed on day 20 of admission due to the 
expected long-term need for nutrition support. After PLEX treatment was completed on day 24, 
the patient showed some minor improvements in the motor function in his limbs. However, he 
continued to experience respiratory difficulty and was unable to swallow. 
Eventually, the patient was accepted by the long-term acute care hospital (LTACH) at Mission 
Hospital, where he continued to receive occupational and physical therapy, enteral nutrition, and 
respiratory support. 
IV. Nutritional evaluation and treatment 
The Clinical Nutrition Team (CNT) and the Metabolic Support Service (MSS) were consulted 
frequently throughout the patient’s hospitalization to provide nutrition recommendations and 
support.  
The patient was first seen by the CNT 5 days after admission, after transfer out of the MSICU. 
His weight was 124.3 kg and height was 190.5 cm. The Mifflin St. Jeor equation (x 1-1.1 activity 
factor) estimated his caloric needs at 2162-2378 kcal/day. His protein needs were estimated to be 
99-134 g/day based on 0.8-1 g/kg body weight. At that time the patient was consuming 75-100% 
of the meals provided and reported that he did not have any issues with swallowing. The patient 
was on a regular oral diet, which provided around 1800 kcals and 91 grams protein per day. 
Because the patient was eating well, the CNT unfortunately did not implement any dietary 
interventions. 
After the patient transferred to the MSICU on day 8, nutrition care was transferred to a MSS 
dietitian. On day 9, his weight was 110.1 kg, an 11% weight loss in 9 days. The MSS dietitian 
diagnosed the patient as moderately malnourished due to weight loss and a presumed energy 
intake less than his estimated needs in the setting of acute illness according to ASPEN 
malnutrition criteria10 (Table 1). 
 
Table 1 Clinical Characteristics to Support a Diagnosis of Malnutrition. Adapted from 
Characteristics Recommended for the Identification and Documentation of Adult Malnutrition 
(Undernutrition). Copyright 2012 Journal of Parenteral and Enteral Nutrition. 
The MSS dietitian added a multivitamin with minerals to the patient’s diet in order to meet his 
micronutrient needs. In addition, to provide additional calories and protein due to excessive 
weight loss, the MSS dietitian ordered oral supplements of Ensure Plus shakes three times a day 
with meals, as well as Core Power high protein shakes. Each Ensure Plus potentially provided 
the patient with an extra 350 kcal and 13 grams of protein, while Core Power provided 240 kcal 
and 26 g protein. Unfortunately, consumption of both meals and supplements were not well 
documented after the patient left the MSICU the second time. At that time the patient also 
required assistance feeding himself due to weakness and numbness of both arms.  
When the patient experienced respiratory difficulty day 9, he was put a full liquid diet for 5 days. 
The full liquid diet consisted of liquids as well as solid foods that turn to liquid at room 
temperature, providing minimal calories. On day 13, a regular oral diet was provided once again, 
but with the texture modification of chopped meats following the VFSS on day 11, which 
showed mild pharyngeal dysphagia. After transfer out of the MSICU he was seen again by the 
CNT on day 13. The CNT recommended frequent weight checks as well as skin integrity checks 
due to his rapid weight loss and immobility. The dietitian also educated the patient on the need 
for consistent meal intake as well as high protein intake due to risk of muscle loss and skin 
breakdown.  
When the patient returned to MSICU a third time 15 days after admission, tube feedings were 
initiated by the MSS dietitian because the patient was intubated and no longer able to swallow. 
Caloric needs were calculated based on the Penn State 2003 equation. Estimation indicated that 
the patient would need 2215 kcal/day. Protein needs were estimated to be 1-1.2 g/kg, or 110-132 
g per day, based on his most recent weight of 110.1 kg. Promote, an enteral nutrition formula, 
was administered at 70 mL/h to provide 1680 kcal and 105 g protein/day. A protein module, Pro-
Stat, was administered once daily to provide an additional 100 kcal and 15 g of protein11 (Figure 
2). The dietitian aimed to provide lower than his estimated needs due to the infusion of propofol, 
a drug used for sedation and administered in a lipid emulsion, providing 1.1 kcal/mL as fat12. 
I saw the patient on the 18th day of admission when he was in the MSICU. Propofol had been 
discontinued because the patient no longer required sedation and was not meeting his estimated 
calorie or protein needs due to the loss of calories provided by this drug. I calculated his energy 
needs based on his most recent weight of 116 kg and used the Penn State 2003 equation. His 
estimated energy needs were 2375 kcal/kg.  His BMI was 31.96, suggesting obesity. ASPEN 
guidelines recommend permissive underfeeding for intubated obese patients (22-25 kcals/kg 
ideal body weight)13; however, because he was formerly a wrestler and was an avid weight lifter, 
I used clinical judgment and provided a tube feeding based on the estimated needs determined 
with the Penn State 2003 equation. Due to his previous rapid weight loss, I also estimated his 
protein needs as 1.3-1.5 g/kg, or 151-174 g protein/day. I changed his enteral formula to 
Osmolite 1.2 at 70 mL/hr plus the protein module Pro-Stat 3 times a day to provide 2316 kcals 
and 138 g protein (Figure 2). 
 
Table 2 Adult Enteral Formulas. Adapted from Adult Enteral Nutrition Formulary. Copyright 
2012 Mission Hospital. 
Due to the previous diagnosis of moderate malnutrition and excessive weight loss in a short time 
frame despite eating 75-100% of his diet order prior to intubation and placement of a feeding 
tube, I wondered if he had elevated calorie needs. To gain a more precise picture of his resting 
energy expenditure (REE), I ordered a metabolic cart study.   
A metabolic cart determines REE using indirect calorimetry, the gold standard for determining 
energy requirements. The cart measures oxygen consumption and carbon dioxide production; 
every liter of oxygen consumed is equivalent to 5 calories of energy. The key to accurately 
determining REE is collecting all inspired and expired air.  Metabolic cart studies are most 
accurate when the patient has consistent intake. A patient either needs to be NPO (nothing passed 
orally) or on a stable tube feeding when the cart study is performed. Studies are most easily 
performed when a patient is intubated, because his respiratory rate is steady. Because I had 
changed the formula of the tube feeding, I knew the cart study could only be performed in a 
small window of time. I spoke with the technician, who made an effort to see the patient before 
the new enteral formula was initiated. The metabolic cart study showed that instead of the 
estimated REE of 2375, the patient’s actual REE was 3081 kcal.  
I researched the metabolic process of GBS, and found that both hypermetabolism and 
hypercatabolism were major components of the syndrome, specifically within the first 2-4 weeks 
of onset. When a metabolic cart study is performed and a patient’s BMI is above 30, guidelines 
recommend feeding the patient approximately 70% of his REE13. The enteral formula that I 
recommended provided the patient with 75% of his REE, and no further changes were made to 
his enteral nutrition order.  
The week after I saw the patient, a urine urea nitrogen sample was collected and showed neither 
positive nor negative nitrogen balance. No net loss or gain of nitrogen in the urine indicated that 
the patient received an adequate amount of protein in his tube feeding, and no further muscle 
wasting occurred despite hypercatabolism.  
V. Progress and prognosis of the patient  
Early during his hospitalization, the patient became progressively weaker, beginning in his lower 
extremities followed by his upper extremities. Eventually, he experienced respiratory distress, 
was unable to clear secretions in his airways, and required intubation and enteral nutrition 
support. 
The patient required ongoing respiratory support, so a tracheotomy tube was placed 19 days after 
admission. In addition, 20 days after admission, a PEG tube was placed for ongoing nutrition 
support. When the tracheotomy tube was placed, a culture of lung secretions showed that the 
patient had developed a hospital-acquired pneumonia. He was placed on several antibiotics.  
The patient received typical treatments to alleviate the symptoms of GBS. Initially he was given 
a course of IVIG treatment, with no noted improvement. He then underwent 5 PLEX treatments. 
After PLEX concluded, limited improvement was noted. He was able to wiggle his toes and 
move his arms but was still unable to feed himself and had difficulty breathing on his own.  
After enteral nutrition support was initiated, the patient did not continue to lose weight. Due to 
his prolonged intubation and his loss of swallowing functionality, he remained on tube feedings 
during the rest of his hospitalization. 
The physicians remained hopeful that the patient would slowly regain his strength. When he was 
stable in the MSICU, he worked extensively with physical and occupational therapists. Due to 
his expected prolonged recovery and need for multiple allied health professional support, he was 
transferred to the LTACH at Mission Hospital. He was placed at LTACH one month after 
admission.  
VI. Summary 
This patient presented interesting challenges due to my limited knowledge of the effect of GBS 
on metabolism. The patient lost excessive weight during his hospitalization, meaning that he was 
underfed during his stay. This was due to receiving inadequate calories while consuming the 
regular hospital diet, and additionally from receiving a full liquid diet for 5 days.  A regular oral 
diet at Mission Memorial Hospital on average provides 1800 calories and 91 grams of protein. 
Even when the patient was eating 100% of his meals, he could not meet his REE 3081 calories, 
causing him to lose weight rapidly. Working on this case underscored, for me, the importance of 
understanding disease processes, obtaining weekly weights of patients, and abating unnecessary 
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